Your browser doesn't support javascript.
loading
FERN: is it possible to conduct a randomised controlled trial of intervention or expectant management for early-onset selective fetal growth restriction in monochorionic twin pregnancy - protocol for a prospective multicentre mixed-methods feasibility study.
Khalil, Asma; Prasad, Smriti; Woolfall, Kerry; Mitchell, Tracy Karen; Kirkham, Jamie J; Yaghi, Odai; Ricketts, Tracey; Attilakos, George; Bailie, Carolyn; Cornforth, Christine; Denbow, Mark; Hardman, Louise; Harrold, Jane; Parasuraman, Rajeswari; Leven, Shauna; Marsden, Joel; Mendoza, Jessica; Mousa, Tommy; Nanda, Surabhi; Thilaganathan, Baskaran; Turner, Mark; Watson, Michelle; Wilding, Karen; Popa, Mariana; Alfirevic, Zarko; Anumba, Dilly; Ashcroft, Richard Edmund; Baschet, Ahmet; da Silva Costa, Fabrício; Deprest, Jan; Fenwick, Natasha; Haak, Monique C; Healey, Andy; Hecher, Kurt; Impey, Lawrence; Jackson, Richard J; Johnstone, Edward D; Lewi, Liesbeth; Lopriore, Enrico; Papageorghiou, Aris T; Pasupathy, Dharmintra; Sandall, Jane; Sharp, Andrew; Thangaratinam, Shakila; Vollmer, Brigitte; Yinon, Yoav.
Afiliación
  • Khalil A; Fetal Medicine Unit, St George's University Hospital, London, UK akhalil@sgul.ac.uk.
  • Prasad S; Fetal Medicine Unit, Liverpool Women's Hospital, University of Liverpool, Liverpool, UK.
  • Woolfall K; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
  • Mitchell TK; Fetal Medicine Unit, St George's University Hospital, London, UK.
  • Kirkham JJ; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
  • Yaghi O; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
  • Ricketts T; Centre for Biostatistics, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Attilakos G; Fetal Medicine Unit, St George's University Hospital, London, UK.
  • Bailie C; Department of Women's and Children's Health, Faculty of Health & Life Sciences, Harris Wellbeing of Women Research Centre, University of Liverpool, Liverpool, UK.
  • Cornforth C; Women's Health Division, University College London Hospitals NHS Foundation Trust, Institute for Women's Health, University College London, London, UK.
  • Denbow M; Royal Jubilee Maternity Hospital, Belfast, UK.
  • Hardman L; Department of Women's and Children's Health, Faculty of Health & Life Sciences, Harris Wellbeing of Women Research Centre, University of Liverpool, Liverpool, UK.
  • Harrold J; Fetal Medicine Unit, St Michael's Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
  • Parasuraman R; Liverpool Women's NHS Foundation Trust, Liverpool, UK.
  • Leven S; Department of Women's and Children's Health, Faculty of Health & Life Sciences, Harris Wellbeing of Women Research Centre, University of Liverpool, Liverpool, UK.
  • Marsden J; Wessex Fetal Maternal Medicine unit, University Southampton NHS Foundation Trust, Princess Anne Hospital, Southampton, UK.
  • Mendoza J; Twins Trust, The Manor House, Aldershot, UK.
  • Mousa T; PPIE, FERN project, Liverpool, UK.
  • Nanda S; PPIE, FERN project, Liverpool, UK.
  • Thilaganathan B; University of Leicester, Leicester, UK.
  • Turner M; Guy's and St Thomas's Hospital, London, UK.
  • Watson M; Fetal Medicine Unit, St George's University Hospital, London, UK.
  • Wilding K; Department of Women's and Children's Health, Faculty of Health & Life Sciences, Harris Wellbeing of Women Research Centre, University of Liverpool, Liverpool, UK.
  • Popa M; PPIE, FERN project, Liverpool, UK.
  • Alfirevic Z; Clinical Directorate, Faulty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
  • Anumba D; Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK.
  • Ashcroft RE; Department of Women's and Children's Health, Faculty of Health & Life Sciences, Harris Wellbeing of Women Research Centre, University of Liverpool, Liverpool, UK.
  • Baschet A; Academic Unit of Reproductive and Developmental Medicine, Department of Human Metabolism, University of Sheffield, Sheffield, UK.
  • da Silva Costa F; School of Law, City University of London, London, UK.
  • Deprest J; Johns Hopkins Center for Fetal Therapy Department of Gynecology & Obstetrics, Johns Hopkins University, Baltimore, Maryland, USA.
  • Fenwick N; Maternal Fetal Medicine Unit, Gold Coast University Hospital, Gold Coast, Queensland, Australia.
  • Haak MC; Fetal Medicine Unit, Dept. Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium.
  • Healey A; Dept of Development and Regeneration, Biomedical Sciences, KU Leuven, Leuven, Belgium.
  • Hecher K; Twins Trust, The Manor House, Aldershot, UK.
  • Impey L; Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, Netherlands.
  • Jackson RJ; King's Health Economics, Health Service, and Population Research Department, King's College London, London, UK.
  • Johnstone ED; Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lewi L; Department of Fetal Medicine, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Lopriore E; Department of Statistics, Liverpool Clinical Trials Unit, University of Liverpool, Liverpool, UK.
  • Papageorghiou AT; Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical Sciences, Faculty of Medicine Biology and Health, University of Manchester, Manchester, UK.
  • Pasupathy D; Fetal Medicine Unit, Dept. Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium.
  • Sandall J; Dept of Development and Regeneration, Biomedical Sciences, KU Leuven, Leuven, Belgium.
  • Sharp A; Department of Paediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, Netherlands.
  • Thangaratinam S; Fetal Medicine Unit, St George's University Hospital, London, UK.
  • Vollmer B; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.
  • Yinon Y; Reproduction and Perinatal Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
BMJ Open ; 14(8): e080021, 2024 Aug 17.
Article en En | MEDLINE | ID: mdl-39153765
ABSTRACT

INTRODUCTION:

Selective fetal growth restriction (sFGR) in monochorionic twin pregnancy, defined as an estimated fetal weight (EFW) of one twin <10th centile and EFW discordance ≥25%, is associated with stillbirth and neurodisability for both twins. The condition poses unique management difficulties on the one hand, continuation of the pregnancy carries a risk of death of the smaller twin, with a high risk of co-twin demise (40%) or co-twin neurological sequelae (30%). On the other, early delivery to prevent the death of the smaller twin may expose the larger twin to prematurity, with the associated risks of long-term physical, emotional and financial costs from neurodisability, such as cerebral palsy.When there is severe and early sFGR, before viability, delivery is not an option. In this scenario, there are currently three main management options (1) expectant management, (2) selective termination of the smaller twin and (3) placental laser photocoagulation of interconnecting vessels. These management options have never been investigated in a randomised controlled trial (RCT). The best management option is unknown, and there are many challenges for a potential RCT. These include the rarity of the condition resulting in a small number of eligible pregnancies, uncertainty about whether pregnant women will agree to participate in such a trial and whether they will agree to be randomised to expectant management or active fetal intervention, and the challenges of robust and long-term outcome measures. Therefore, the main objective of the FERN study is to assess the feasibility of conducting an RCT of active intervention vs expectant management in monochorionic twin pregnancies with early-onset (prior to 24 weeks) sFGR. METHODS AND

ANALYSIS:

The FERN study is a prospective mixed-methods feasibility study. The primary objective is to recommend whether an RCT of intervention vs expectant management of sFGR in monochorionic twin pregnancy is feasible by exploring women's preference, clinician's preference, current practice and equipoise and numbers of cases. To achieve this, we propose three distinct work packages (WPs). WP1 A Prospective UK Multicentre Study, WP2A a Qualitative Study Exploring Parents' and Clinicians' Views and WP3 a Consensus Development to Determine Feasibility of a Trial. Eligible pregnancies will be recruited to WP1 and WP2, which will run concurrently. The results of these two WPs will be used in WP3 to develop consensus on a future definitive study. The duration of the study will be 53 months, composed of 10 months of setup, 39 months of recruitment, 42 months of data collection, and 5 months of data analysis, report writing and recommendations. The pragmatic sample size for WP1 is 100 monochorionic twin pregnancies with sFGR. For WP2, interviews will be conducted until data saturation and sample variance are achieved, that is, when no new major themes are being discovered. Based on previous similar pilot studies, this is anticipated to be approximately 15-25 interviews in both the parent and clinician groups. Engagement of at least 50 UK clinicians is planned for WP3. ETHICS AND DISSEMINATION This study has received ethical approval from the Health Research Authority (HRA) South West-Cornwall and Plymouth Ethics Committee (REC reference 20/SW/0156, IRAS ID 286337). All participating sites will undergo site-specific approvals for assessment of capacity and capability by the HRA. The results of this study will be published in peer-reviewed journals and presented at national and international conferences. The results from the FERN project will be used to inform future studies. TRIAL REGISTRATION NUMBER This study is included in the ISRCTN Registry (ISRCTN16879394) and the NIHR Central Portfolio Management System (CPMS), CRN Reproductive Health and Childbirth Specialty (UKCRN reference 47201).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ensayos Clínicos Controlados Aleatorios como Asunto / Estudios de Factibilidad / Retardo del Crecimiento Fetal / Embarazo Gemelar Límite: Female / Humans / Newborn / Pregnancy Idioma: En Revista: BMJ Open Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ensayos Clínicos Controlados Aleatorios como Asunto / Estudios de Factibilidad / Retardo del Crecimiento Fetal / Embarazo Gemelar Límite: Female / Humans / Newborn / Pregnancy Idioma: En Revista: BMJ Open Año: 2024 Tipo del documento: Article